Selective estrogen receptor modulators (SERMs), also known as estrogen receptor agonists/antagonists (ERAAs), are a class of drugs that act on estrogen...
58 KB (6,598 words) - 18:11, 25 May 2025
A selective estrogen receptor degrader or downregulator (SERD) is a type of drug that selectively binds to the estrogen receptor (ER) and induces its degradation...
6 KB (477 words) - 09:41, 6 March 2025
Fulvestrant (category Selective estrogen receptor degraders)
Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing...
27 KB (2,341 words) - 07:28, 2 November 2024
LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer". Journal of...
2 KB (236 words) - 03:37, 28 March 2025
Elacestrant (category Selective estrogen receptor degraders)
Elacestrant, sold under the brand name Orserdu, is a selective estrogen receptor degrader (SERD) used in the treatment of breast cancer. It is taken by...
13 KB (908 words) - 20:41, 29 May 2025
Estrogen receptors (ERs) are proteins found in cells that function as receptors for the hormone estrogen (17β-estradiol). There are two main classes of...
38 KB (4,062 words) - 09:59, 22 May 2025
Antihormone therapy (section SERMs (selective estrogen receptor modulator) and SERDs (selective estrogen receptor degrader))
prescribed to selectively block estrogen's effect on certain cells. SERMs like tamoxifen attach to receptors on the cancer cells which blocks estrogen from attaching...
11 KB (1,058 words) - 07:53, 4 January 2025
Antiestrogen (redirect from Estrogen receptor antagonists)
include selective estrogen receptor modulators (SERMs) like tamoxifen, clomifene, and raloxifene, the ER silent antagonist and selective estrogen receptor degrader...
8 KB (745 words) - 20:56, 24 November 2024
Camizestrant (category Selective estrogen receptor degraders)
evaluated to treat breast cancer. It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD). "Camizestrant - AstraZeneca"...
3 KB (84 words) - 08:50, 3 November 2024
Giredestrant (category Selective estrogen receptor degraders)
investigational oral selective estrogen receptor degrader (SERD) developed by Genentech, a member of the Roche Group, for the treatment of estrogen receptor-positive...
16 KB (1,239 words) - 18:53, 30 May 2025
Estrogen receptor alpha (ERα), also known as NR3A1 (nuclear receptor subfamily 3, group A, member 1), is one of two main types of estrogen receptor, a...
58 KB (6,133 words) - 02:11, 17 March 2025
Amcenestrant (category Selective estrogen receptor degraders)
Amcenestrant is a novel oral selective estrogen receptor degrader (SERD) that is being evaluated for the treatment of estrogen receptor-positive (ER+) breast...
7 KB (270 words) - 07:48, 17 April 2025
Antiandrogen (redirect from Androgen receptor antagonist)
the degradation of the AR, and are analogous to selective estrogen receptor degraders (SERDs) like fulvestrant (a drug used to treat estrogen receptor-positive...
161 KB (15,261 words) - 19:58, 29 May 2025
Palazestrant (category Selective estrogen receptor degraders)
both a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD). This orally bioavailable small molecule has demonstrated...
5 KB (123 words) - 07:49, 17 April 2025
Rintodestrant (category Selective estrogen receptor degraders)
orally bioavailable selective estrogen receptor degrader (SERD) developed by G1 Therapeutics for the treatment of estrogen receptor-positive (ER+) breast...
5 KB (147 words) - 09:43, 30 November 2024
Imlunestrant (category Selective estrogen receptor degraders)
Imlunestrant is an experimental selective estrogen receptor degrader developed by Eli Lilly and Company for the treatment of some types of breast cancer...
6 KB (313 words) - 08:51, 3 November 2024
Taragarestrant (category Selective estrogen receptor degraders)
orally bioavailable selective estrogen receptor degrader (SERD) developed by Inventis Bio for the treatment of estrogen receptor-positive (ER+) breast...
5 KB (168 words) - 07:50, 17 April 2025
receptor degrader for breast cancer [29] Imlunestrant (LY-3484356) – selective estrogen receptor modulator and selective estrogen receptor degrader for...
15 KB (1,243 words) - 23:07, 8 May 2025
Vepdegestrant (category Selective estrogen receptor degraders)
an experimental estrogen receptor degrader that works via proteolysis targeting chimera. It is developed for advanced estrogen receptor positive breast...
4 KB (173 words) - 18:29, 21 October 2024
Estrogen receptor beta (ERβ) also known as NR3A2 (nuclear receptor subfamily 3, group A, member 2) is one of two main types of estrogen receptor—a nuclear...
39 KB (4,526 words) - 06:00, 25 July 2024
Aromatase inhibitor (section Non-selective)
][better source needed] CYP17A1 inhibitor Estrogen deprivation therapy Selective estrogen receptor degrader Hassett, Michael J.; Somerfield, Mark R.;...
21 KB (2,089 words) - 16:27, 23 May 2025
Bexirestrant (category Selective estrogen receptor degraders)
Bexirestrant is a selective estrogen receptor degrader (SERD) which is being evaluated for the treatment of breast cancer. This orally bioavailable compound...
5 KB (110 words) - 07:48, 17 April 2025
Brilanestrant (category Selective estrogen receptor degraders)
RO-7056118) is a nonsteroidal combined selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD) that was discovered by Aragon...
8 KB (549 words) - 14:31, 24 April 2025
A (selective) androgen receptor degrader or downregulator (SARD) is a type of drug which interacts with the androgen receptor (AR) such that it causes...
4 KB (339 words) - 18:32, 17 November 2024
Etacstil (category Selective estrogen receptor degraders)
combined selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD) that was developed for the treatment of estrogen receptor-positive...
8 KB (695 words) - 05:38, 14 March 2025
Endocrine therapy is a common treatment for estrogen receptor positive breast cancer. However, resistance to this therapy can develop, leading to relapse...
27 KB (3,317 words) - 16:11, 23 May 2025
Bazedoxifene (category Selective estrogen receptor degraders)
possibly (pending more study) for cancer. It is a third-generation selective estrogen receptor modulator (SERM). Since late 2013 it has had U.S. FDA approval...
7 KB (491 words) - 20:06, 29 May 2025
chemotherapy followed by avelumab. Rintodestrant, an oral selective estrogen receptor degrader (SERD), is being developed as a treatment for ER-Positive...
21 KB (2,109 words) - 20:55, 29 May 2025
ZB716 (category Selective estrogen receptor degraders)
estrogen receptor (ER)-positive metastatic breast cancer. The drug is a silent antagonist of the ERα (IC50 = 4.1 nM) as well as a selective estrogen receptor...
5 KB (334 words) - 03:23, 12 January 2024
Bisphenol A (redirect from Bisphenol a degradation)
hormone receptors, in both humans and animals. It binds to both of the nuclear estrogen receptors (ERs), ERα and ERβ. BPA is a selective estrogen receptor modulator...
67 KB (7,001 words) - 23:14, 23 May 2025